These latter data clearly demonstrated that the time-window for effective therapeutic intervention in SMA mice was restricted to the first post-natal days and that most likely no overt levels of the FL-SMN protein were required in the adult period [44]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.